An observational study in SMARCA4-Deficient Tumor and NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Observational
This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's enrollment of 221 is above the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 149 studies on the registry; 91 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The clinical information of 221 patients with advanced non-small cell lung cancer from the Department of Oncology of Shanghai Pulmonary Hospital.
Exclusion Criteria:
Progression-free survival (PFS)
Time from the beginning of first-line therapy to the first progression (PD) in patients with lung cancer
Time frame: 5 years
Overall survival (OS)
Overall survival (OS) is defined as the duration from the beginning of first-line therapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
Time frame: 5 years
Objective Response Rate (ORR)
The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time frame: 5 years
Disease control rate (DCR)
Disease control rate (DCR) was defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Time frame: 5 years
The correlation between tumor immune microenvironment and therapeutic efficacy
Multiplex immunofluorescence staining was performed on pathological specimens from individuals diagnosed with SMARCA4-deficient lung cancer who underwent immune combination chemotherapy.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Shanghai Pulmonary Hospital, Shanghai, China